This HTML5 document contains 78 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01265/identifier/pubchem-substance/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01265/identifier/drugbank/
n10http://linked.opendata.cz/resource/AHFS/
n16http://linked.opendata.cz/resource/mesh/concept/
n23http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n13http://linked.opendata.cz/resource/drugbank/dosage/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01265/identifier/national-drug-code-directory/
n27http://bio2rdf.org/drugbank:
n25http://linked.opendata.cz/resource/drugbank/drug/DB01265/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n26http://www.rxlist.com/cgi/generic/
n7http://linked.opendata.cz/resource/drugbank/patent/
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n28http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n15http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01265/identifier/pharmgkb/
n5http://www.drugs.com/cdi/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n24http://linked.opendata.cz/resource/drugbank/drug/DB01265/identifier/bindingdb/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01265/identifier/pubchem-compound/
n9http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01265
rdf:type
n3:Drug
n3:description
Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects.
n3:dosage
n13:271B6122-363D-11E5-9242-09173F13E4C5 n13:271B6123-363D-11E5-9242-09173F13E4C5 n13:271B6124-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Matthews SJ: Telbivudine for the management of chronic hepatitis B virus infection. Clin Ther. 2007 Dec;29(12):2635-53. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18201580 # Amarapurkar DN: Telbivudine: a new treatment for chronic hepatitis B. World J Gastroenterol. 2007 Dec 14;13(46):6150-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18069753 # Dusheiko G, Danta M: Telbivudine for the treatment of chronic hepatitis B. Drugs Today (Barc). 2007 May;43(5):293-304. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17724496 # Keam SJ: Telbivudine. Drugs. 2007;67(13):1917-29. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17722961 # Ruiz-Sancho A, Sheldon J, Soriano V: Telbivudine: a new option for the treatment of chronic hepatitis B. Expert Opin Biol Ther. 2007 May;7(5):751-61. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17477811 # Marcellin P, Asselah T, Boyer N: Treatment of chronic hepatitis B. J Viral Hepat. 2005 Jul;12(4):333-45. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15985003 # Han SH: Telbivudine: a new nucleoside analogue for the treatment of chronic hepatitis B. Expert Opin Investig Drugs. 2005 Apr;14(4):511-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15882124 # Jones R, Nelson M: Novel anti-hepatitis B agents: A focus on telbivudine. Int J Clin Pract. 2006 Oct;60(10):1295-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16981973
n3:group
investigational approved
n3:halfLife
Approximately 15 hours.
n3:indication
For the treatment of chronic hepatitis B in adult and adolescent patients ≥16 years of age with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
owl:sameAs
n12:DB01265 n27:DB01265
dcterms:title
Telbivudine
adms:identifier
n18:159269 n19:46508706 n20:0078-0539-85 n21:PA164760861 n22:DB01265 n24:50156567 n25:140081
n3:mechanismOfAction
Telbivudine 5'–triphosphate inhibits HBV DNA polymerase (reverse transcriptase) by competing with the natural substrate, thymidine 5'–triphosphate. This leads to the chain termination of DNA synthesis, thereby inhibiting viral replication. Incorporation of telbivudine 5'–triphosphate into viral DNA also causes DNA chain termination, resulting in inhibition of HBV replication. Telbivudine inhibits anticompliment or second-strand DNA.
n3:packager
n23:271B6120-363D-11E5-9242-09173F13E4C5 n23:271B611F-363D-11E5-9242-09173F13E4C5
n3:patent
n7:6395716 n7:2340156 n7:7589079
n3:routeOfElimination
Telbivudine is eliminated primarily by urinary excretion of unchanged drug.
n3:synonym
Beta-l-thymidine 1-(2-Deoxy-beta-L-ribofuranosyl)-5-methyluracil LDT Telbivudin Epavudine beta-L-2'-Deoxythymidine L-thymidine L-DT 2'-Deoxy-L-thymidine L-deoxythymidine
n3:toxicity
There is no information on intentional overdose of telbivudine, but one subject experienced an unintentional and asymptomatic overdose. Healthy subjects who received telbivudine doses up to 1800 mg/day for 4 days had no increase in or unexpected adverse events. A maximum tolerated dose for telbivudine has not been determined.
n8:hasAHFSCode
n10:08-18-08-20
n3:foodInteraction
Take without regard to meals.
n3:proteinBinding
In vitro binding of telbivudine to human plasma proteins is low (3.3%).
n15:hasConcept
n16:M0469133
foaf:page
n5:telbivudine.html n26:tyzeka.htm
n3:IUPAC-Name
n6:271B6129-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B612F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B612E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B612B-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B612C-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B612D-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n6:271B6127-363D-11E5-9242-09173F13E4C5 n6:271B613F-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B6125-363D-11E5-9242-09173F13E4C5 n6:271B6128-363D-11E5-9242-09173F13E4C5 n6:271B6140-363D-11E5-9242-09173F13E4C5
n3:logS
n6:271B6126-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n9:J05AF11
n3:H-Bond-Acceptor-Count
n6:271B6135-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B6136-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B6130-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B6131-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B6133-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B6132-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B6134-363D-11E5-9242-09173F13E4C5
n3:absorption
Absorbed following oral administration. Telbivudine absorption and exposure were unaffected when a single 600–mg dose was administered with a high–fat (~55 g), high–calorie (~950 kcal) meal.
n3:affectedOrganism
Hepatitis B virus
n3:casRegistryNumber
3424-98-4
n3:clearance
* 7.6 +/- 2.9 L/h [Normal renal function (Clcr>80 mL/min)] * 5.0 +/- 1.2 L/h [Mild renal function impairement (Clcr=50-80 mL/min)] * 2.6 +/- 1.2 L/h [Moderate renal function impairement (Clcr=30-49 mL/min)] * 0.7 +/- 0.4 L/h [Severe renal function impairement (Clcr<30 mL/min)]
n3:containedIn
n28:271B6121-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n6:271B613B-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B613D-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B613E-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B613A-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B6139-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B613C-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B612A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n6:271B6137-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B6138-363D-11E5-9242-09173F13E4C5